Oxaliplatin: A new agent for colorectal cancer

Current Oncology Reports

Volumn 3, Issue 2, 2001, Pages 147-155

  Pelley, Robert J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clin Oncol; Colorectal Cancer; Irinotecan; Maximum Tolerate Dose; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

CLINICAL TRIAL; COLORECTAL TUMOR; DRUG APPROVAL; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; PATHOLOGY; REVIEW; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0035286255     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0015-6     Document Type: Article

References (49)

1. Cunningham D, Pyrhonen S, James RD, et al.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413–1418. DOI: 10.1016/S0140-6736(98)02309-5
2. Rougier P, Man Cutsem E, Bajetta E, et al.: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407–1412. DOI: 10.1016/S0140-6736(98)03085-2
3. Saltz LB, Locker PK, Pirotta N, et al.: Weekly irinotecan (CPT-11), leucovorin, and fluorouracil is superior to daily x 5 leucovorin + 5-FU in patients with previously untreated metastatic colorectal cancer [abstract]. Proc ASCO 1999, 18:233.
4. Douillard JY, Cunningham D, Roth AD, et al.: A randomized phase III trial comparing irinotecan + 5-FU + folinic acid to the same schedule of 5-FU+ folinic acid in patients with metastatic colorectal cancer as front line chemotherapy. Lancet 2000, 355:1041–1047. DOI: 10.1016/S0140-6736(00)02034-1
5. Rixe O, Ortuzar W, Alvarez M, et al.: Oxaliplatin, tetraplatin, cesplatin, and carboplatin: spectrum of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855–1865. DOI: 10.1016/S0006-2952(97)81490-6
6. Kidani Y, Inagaki K, Saito R, et al.: Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclo hexane isomers and their related derivatives. J Clin Hematol Oncol 1977, 7:197–209.
7. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993, 53:799–805.
8. Fink D, Zheng H, Nebel S, et al.: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997, 57:1841–1845.
9. Raymond E, Sandrine F, Woynarowski JM, Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25(suppl 5):4–15. Excellent general review of mechanism of action of oxaliplatin with recent evidence for relationship to MMR cellular defects.
10. Mathe G, Kidani Y, Triana K, et al.: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed Pharmacolther 1986, 40:372–376.
11. Extra JM, Espie M, Calvo F, et al.: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25:299–303. DOI: 10.1007/BF00684890
12. Caussanel JP, Levi F, Brienza S, et al.: Phase I trial of five-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82:1046–1050. DOI: 10.1093/jnci/82.12.1046
13. Massari C, Brienza S, Rotarski M, et al.: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 2000, 45:157–164. This pharmocokinetic study was reported in abstract form in 1994. In this recent report, the authors carefully document the dependence of oxaliplatin clearance on renal function, and the lack of associated increased toxicity in patients with renal impairment. DOI: 10.1007/s002800050024
14. Gamelin E, Le Bouil A, Boisdron-Celle M, et al.: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997, 3:891–899.
15. Wasserman E, Cuvier C, Lokiec F, et al.: Combination of oxaliplatin plus irinotecan in patients with gastrointentinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999, 17:1751–1759. Well-performed phase I trial with important pharmacokinetic studies.
16. Kern W, Braess J, Böttger B, et al.: Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999, 5:761–765.
17. Bécouarn Y, Ychou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998, 16:2739–2744. Carefully performed phase II study establishing the activity of oxaliplatin at a dose of 130 mg/m2 every 3 weeks. The response rate was 25% in previously untreated patients, confirming oxaliplatin as one of the three most active single agents in colorectal cancer.
18. Diaz-Rubio E, Sastre J, Zaniboni A, et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998, 9:105–108. This reported study is smaller than the preceding one but is important as well because of its confirmation of the single-agent activity of oxaliplatin in previously untreated patients. DOI: 10.1023/A:1008200825886
19. Lévi F, Perpoint B, Garufi C, et al.: Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993, 29A:1280–1284. DOI: 10.1016/0959-8049(93)90073-O
20. Machover D, Diaz-Rubio E, de Gramont A, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95–98.
21. L’evi F, Misset J, Brienza S, et al.: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992, 69:893–900. DOI: 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X
22. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al.: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:2950–2958.
23. Lévi F, Zidani R, Brienza S, et al.: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer 1999, 85:2532–2540. DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1
24. Giacchetti S, Itzhaki M, Gruia G, et al.: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10:663–669. This recent retrospective review is one of the largest series of patients undergoing hepatic resection for colorectal metastases following systemic treatment with oxaliplatin. The authors emphasize the benefits of downstaging tumors previously defined as unresectable. DOI: 10.1023/A:1008347829017
25. Lévi F, Zidani R, Vannetezel J, et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86:1608–1617. DOI: 10.1093/jnci/86.21.1608
26. Lévi F, Zidani R, Misset J, et al.: Randomised muilticentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997, 350:681–686. DOI: 10.1016/S0140-6736(97)03358-8
27. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136–147. One of two randomized phase III trials used as a pivotal trial for FDA licensing. An example in oncology that response rate and progressionfree survival do not always translate into significant overall survival.
28. de Gramont A, Figer A, Seymour M, et al.: A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) [abstract]. Proc ASCO 1998, 17:257. Reported only in abstract form, this study is important because it was also used for the FDA licensing application. The 5-FU regimen did not include chronomodulation and is being used as an arm in current US trials.
29. André T, Louvet C, Raymond E, et al.: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FLOFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998, 9:1251–1253. DOI: 10.1023/A:1008475122124
30. Maindrault-Goebel F, Louvet C, André T, et al.: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999, 35:1338–1342. DOI: 10.1016/S0959-8049(99)00149-5
31. André T, Bensmaine M, Louvet C, et al.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999, 17:3560–3568.
32. Bleiberg H, de Gramont A: Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998, 25(suppl 5):32–39.
33. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al.: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:2950–2958.
34. Brienza S, Levi F, Valori VM, et al.: Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients with metastatic colorectal cancer [abstract]. Proc ASCO 1993, 12:197.
35. Meyer V, Delva R, Gamelin E, et al.: Oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients [abstract]. Eur J Cancer 1997, 33:S167. DOI: 10.1016/S0959-8049(96)00360-7
36. Gerard B, Bleiberg H, Michel J, et al.: Oxaliplatin combined with 5-FU and folinic acid (5-FU/FA) as second or third line treatment in patients with advanced colorectal cancer [abstract]. Proc ASCO 1997, 16:228.
37. Louvet C, Bleiberg H, Gamelin E, et al.: Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU-resistant colorectal cancer (CRC) patients is independent of FU + FA schedule [abstract]. Proc ASCO 1996, 15:206.
38. Bensmaine A, Marty M, de Gramont A, et al.: Extended Access French Program (EAFP) of oxaliplatin (OXA) + 5-FU in 5-FU refractory advanced colorectal cancer (RACRC) patients. Proc ASCO 1999, 18:253a.
39. Mitchell EP, LoRusso P, Gococo K, et al.: Safety profile of oxaliplatin (single agent or with 5-FU) from the large North American compassionate use experience in advanced colorectal cancer (ACC). Proc ASCO 2000, 19:1259.
40. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999, 5:1189–1196.
41. Wasserman E, Kalla S, Misset JL, et al.: Oxaliplatin (L-OHP) and irinotecan (CPT-11) phase I/II studies: results in 5 FU refractory (FR) colorectal cancer (CRC) patients [abstract]. Proc ASCO 2000, 19:238.
42. Goldwasser F, Gross M, Tigaud JM, et al.: CPT-11/oxaliplatin (L-OHP) combination every two weeks: final results of a phase I study in advanced digestive malignancies [abstract]. Proc ASCO 1999, 18:259.
43. Scheithauer W, Kornek G, Raderer M, et al.: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorinpretreated colorectal cancer. J Clin Oncol 1999, 17:902–096. This represents one of the first published phase II trials of oxaliplatin combined with CPT-11.
44. Kemeny N, Tong W, Stockman J, et al.: Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer [abstract]. Proc ASCO 2000, 19:948.
45. Lerebours F, Cottu P, Hocini H, et al.: Oxaliplatin (OXA), irinotecan (CPT-11), and 4-day continuous infusion 5-fluorouracil (CIVFU) every three weeks (Q3W): A phase I study in advanced gastrointestinal tumors [abstract]. Proc ASCO 2000, 19:1237.
46. Falcone A, Masi G, Pfanner E, et al.: Phase I-II study of irinotecan (CPT-11), oxaliplatin (L-OHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hours continuous infusion (CI) in metastatic colorectal cancer patients [abstract]. Proc ASCO 2000, 19:1161.
47. Calvo E, Gonzalez-Cao M, Cortes J, et al.: Combined irinotecan, oxaliplatin, 5-FU in patients with metastatic colorectal cancer [abstract. Proc ASCO 2000, 19:1008.
48. Conroy T, Seitz J, Capodano G, et al.: Phase I study of triple combination of oxaliplatin + irinotecan +Lv5fu2 in patients with metastatic solid tumors [abstract.] Proc ASCO 2000, 19:921G.
49. Recchia F, DeFilippis S, Rosselli M, et al.: Randomized phase II study of oxaloplatin (OX) or CPT-11 combined with bimonthly leucovorin and 5-fluorouracil (5-FU) in metastaic colorectal cancer. Preliminary report [abstract]. Proc ASCO 2000, 19:1049.